By adding high concentrations of test drugs to an Ussing chamber with rat jejunum, we established a system that yields very high correlations between the rat absorption percentage and the membrane permeability, and that can accurately predict the absorption percentage for rats. An advantage of this technique is that, unlike the results obtained using Caco-2, the slope of the absorption/membrane-permeability curve is gentle, which facilitates a more exact prediction of the absorption percentage. In addition, the results obtained with this technique demonstrated that it could be used to evaluate the absorption percentage of drugs with an affinity for P-glycoprotein (P-gp), which cannot be assessed using Caco-2. This method also allows for cassette screening, which would facilitate evaluation of the contribution of P-gp to absorption in the small intestine. Cassette screening showed that absorption of fexofenadine was unaffected by combination with the P-gp substrate ketoconazole. Consistent with this finding, in vivo studies showed that ketoconazole did not affect the F a F g for fexofenadine, a pharmacokinetic parameter that reflects absorption and bioavailability in the small intestine. This confirms the usefulness of the Ussing chamber for cassette screening and also suggests that intestinal P-gp has a minimal contribution to drug absorption. (Journal of Biomolecular Screening 2005:517-523) 
INTRODUCTION

T
HERE ARE POOR INTERSPECIES CORRELATIONS between bioavailability (BA) data obtained from experimental animals because BA includes both absorption percentage and clearance factor and because species differences in excretion and metabolism are also contributing factors. Accordingly, there are no interspecies correlations in BA calculated from in vivo studies, and it is impossible to predict BA in humans based on results in animal models. Because it has now become possible to predict metabolism in humans, it should also be possible to predict BA in humans, provided that the absorption percentage can be accurately calculated.
One method of calculating the absorption percentage in experimental animals in the early stages of drug discovery and development is to calculate biliary and urinary excretion rates after oral administration and to consider the total excretion by these routes to be the absorption percentage. Under such circumstances, the identification of metabolites becomes necessary, except in cases in which the administered compound is excreted in the urine and bile without transformation. Combined with the fact that the determination of metabolites in biological samples is very difficult, this becomes extremely labor-intensive work to conduct during the initial screening stages in which unlabeled compounds are used.
Compound absorption is often evaluated during the initial stages of drug discovery by measuring the membrane permeability in Caco-2 cells. Although this method can be very useful for determining the relative permeability of various compounds, the predicted value for the absorption percentage obtained from the permeability coefficient using Caco-2 systems is not reliable because of the steepness of the curves. 1 Another disadvantage of methods using Caco-2 is that the absorption values predicted from the permeability coefficient are underestimated with compounds having affinity for P-gp. [2] [3] [4] [5] The first objective of this study was to investigate the prediction of absorption percentage in rats using an Ussing chamber, which is applicable to the evaluation of drug transport through mucosal membranes, with rat small intestine to facilitate more accurate prediction of absorption percentage in human in vitro studies. An additional objective of this study was to obtain useful information regarding the contribution of intestinal P-gp using this technique.
H (G)]
(SA; 2.96 E 11 Bq/mmol) were purchased from Muromachi Yakuhin (Tokyo, Japan). Krebs-Ringer Bicarbonate buffer powder was purchased from Sigma (St. Louis, MO). Reagents and all compounds were analytical grade. Male, 7-week-old SpragueDawley (SD-IGS) rats were purchased from Charles River Japan, Inc. (Tokyo, Japan). All animals had free access to food and water. The studies reported in this article have been carried out in accordance with the Laboratory Animal Committee of Kissei Pharmaceutical (Nagano, Japan).
Ussing chamber technique
Rats were exsanguinated under ether anesthesia via the abdominal aorta. The jejunum was immediately removed and placed in chilled Krebs-Ringer bicarbonate buffer (pH 6.0; Sigma). Each section of the small intestine was then cut into 2-to 3-cm pieces, which were rinsed and mounted in a diffusion cell. Peyer patches were visually identified and removed to exclude them from the experiment. The exposed intestinal surface area was 0.635 cm 2 . Four milliliters of Krebs-Ringer bicarbonate buffer (pH 6.0; Sigma) was added to the cell on both sides of the membrane. The tissue was maintained at 37°C with continuous bubbling with biogas (O 2 / CO 2 , 95:5). The test compound was then dissolved or suspended in this buffer, which was added to the mucosal side (final concentration of 1.5 and 0.75 mM). Samples (0.1 mL) were taken from the receiving compartment at specified times (1 and 2 h), and were analyzed by high performance liquid chromatography (HPLC) or liquid chromatography-tandem mass spectrometry (LC/MS/MS). When labeled compounds were used, 1-mL samples were taken from the serosal side at specified times, and an additional 1 mL of Krebs-Ringer bicarbonate buffer (pH 6.0; Sigma) was added. Finally, 10 mL of Hionic Fluor (PerkinElmer) was added, and the mixture was thoroughly shaken and left to stand before the radioactivity was measured in a liquid scintillation counter (TriCarb 1900CA, PerkinElmer).
In vivo rat study
Rats were intravenously administered test compound at 1 mg/ kg after the urinary bladder was catheterized with polyethylene tubing. Other rats were fasted for 16 h before dosing and were then administered 3 mg/kg by oral gavage. Blood samples were collected at 1, 5, 15, 30, 60, and 120 min after intravenous administration and at 5, 15, 30, 60, and 120 min after oral administration. Samples (approximately 200 µL) were taken from the jugular vein using a heparin-treated syringe, and plasma was obtained by centrifugation. Urine samples were taken every 30 min for 2 h.
High performance liquid chromatography
An HPLC system consisting of a Hitachi 6000 series liquid chromatograph was used in the determination of norfloxacin, terbutaline, bromocriptine, enarapril, and atenolol. Isocratic elution was performed with a Symmetry Shield RP8 (3.9 × 150 mm; Waters, Milford, MA) with a mobile phase of acetonitrile: 0.01% H 3 PO 4 or 20 mM NaHPO 4 (pH 7.0) at a flow rate of 1.0 mL/min at 50°C. Compounds were detected at 210 nm.
Liquid chromatography-tandem mass spectrometry
Mass spectra were obtained using a Sciex API 365 mass spectrometer (PerkinElmer) equipped with a turbo ion-spray source. Mass Chrom (Version 1.1, PerkinElmer) was the software used to analyze the data acquired. Analysis was performed using a Phenomenex Synergi MAX 80A (4.6 × 50 mm; Phenomenex, Torrance, CA) system with a mobile phase of 50% acetonitrile/ 0.1% AcOH at 50°C at a flow rate of 0.2 mL/min, and it was conducted in positive mode.
Calculation of the membrane permeability coefficient and in vivo kinetic parameters
The final concentrations for the compounds added to the mucosal side were established at 1.5 and 0.75 mM. Serosal concentrations were determined at 1 and 2 h, and the membrane permeation rate at each concentration was calculated from the slope of the concentration-time curve. The membrane permeation rates for the 2 concentrations were then plotted against the added concentrations of the compound, and in vitro rat jejunum permeability (the membrane permeability coefficient) was calculated as the slope of this line.
In vivo analyses were calculated using the following equations:
and
where F is the bioavailability, F a is the absorption percentage, F h is the hepatic bioavailability, and F g is the bioavailability in the small intestine;
CL r = (the amount of urine excretion)/AUC iv /R B ,
where CL r is the renal clearance, CL h is the hepatic clearance, CL tot is the total clearance, and R B is the blood/plasma concentration ratio; and
where Q h is the portal blood flow rate in rats (a value of 55 mL/min/ kg was used). F a F g was then calculated from equations 2 and 6 as follows:
RESULTS
Relationship between the membrane permeability and the absorption percentage using Ussing chamber technique
A total of 10 drugs were selected for comparison between the absorption percentage and the membrane permeability. The absorption percentage of these drugs ranged from 15% to 100%, and a variety of physicochemical properties were selected. The final concentrations of the drug solution or suspension were 0.75 and 1.5 mM in pH 6.0 buffer in the present study, while the membrane permeability was evaluated using µM drug solutions, which corresponds to the Km value in many in vitro studies. The in vitro rat jejunum permeability was calculated using the membrane permeability rates for the 2 concentrations and the added drug concentration. The plotted results revealed a very good correlation between the absorption percentage and the membrane permeability (r = 0.976) (Fig. 1 , Table 1 ). Moreover, the slope of the line calculated from the membrane permeability and the absorption percentage using the Ussing chamber technique was less steep than that produced using Caco-2 1 (17.2 in Ussing chamber and 51.3 in Caco-2), which suggests that the absorption percentage can be more accurately predicted (Fig. 1) .
There is a very good correlation between the membrane permeability and the absorption percentage of drugs evaluated using Caco-2 cells, provided that compounds with an affinity for P-gp are excluded. A good relationship between in vitro rat jejunum permeability and the drug absorption percentage, with drugs having an affinity for P-gp such as digoxin, quinidine, verapamil, and cimetidine, was observed in the Ussing chamber but not in Caco-2 studies 6 ( Fig. 2) . Also, the higher concentration of these drugs did not dissolve in the Ussing chamber system. However, regardless of whether the compounds had an affinity for P-gp or whether they were in solution or suspension, this system allowed the prediction of the rat absorption percentage.
Contribution of intestinal P-gp in drug absorption
To examine the contribution of the intestinal P-gp to drug absorption in our system, we examined the rat jejunum permeability (the membrane permeability coefficient) in vitro for test drugs alone or in combination with drugs that have an affinity for P-gp. The results for the test compounds (verapamil, quinidine, digoxin, and fexofenadine) revealed no significant differences in the absorption percentage (calculated from in vitro rat jejunum permeability), regardless of the concomitant drugs (Table 2 ). Even when 2 or 3 compounds were added simultaneously, the predicted absorption percentage for the test compound was unaffected. Therefore, it appeared that the intestinal P-gp makes a minimal contribution to drug absorption in this system ( Table 2) . A piece of rat jejunum was mounted in a diffusion cell, Krebs-Ringer bicarbonate buffer (pH 6.0) was added to the cell on both sides of the membrane, and biogas (O 2 /CO 2 , 95:5) was passed through at 37°C. The test compound was added to the mucosal side (final concentrations of 1.5 and 0.75 mM), and the sample was taken from the receiving compartment at specified times. The membrane permeation rate at each concentration of the mucosal side was calculated from the slope of the concentration of the serosal side and time curve, and then the membrane permeability coefficient was calculated from the correlation of the membrane permeation rate and the concentration of mucosal side. Pharmacokinetic parameters of fexofenadine with or without ketoconazole in rat in vivo study Figure 3 shows the plasma concentrations of fexofenadine after intravenous administration of 1 mg/kg and after oral administration of 3 mg/kg fexofenadine in rats. Also shown are the plasma concentrations of fexofenadine when ketoconazole was concomitantly administered at the same dose and administration route. The various parameters were calculated from this study ( Table 3 ). The BA of fexofenadine in rats was 1.4%, with a total clearance of 20 mL/min/kg and a renal clearance of 0.3 mL/min/kg. The F h and F a F g calculated from this data were 0.641 and 0.022, respectively. When ketoconazole was concomitantly administered with fexofenadine, the F h and F a F g were 0.713 and 0.017, respectively, which was very similar to when fexofenadine was administered alone. Similarly, Figure 4 shows the plasma concentrations of ketoconazole when administered alone and with concomitant fexofenadine, and the parameters are shown in Table 3 . The plasma concentrations and pharmacokinetic parameters of ketoconazole were almost the same, regardless of the presence of fexofenadine.
DISCUSSION
Many recent reports have demonstrated that active transport plays a critical role in membrane permeability. Drug absorption can be estimated from membrane permeability in cultured cell lines such as Caco-2. Determination of membrane permeability in Caco-2 cells is simple and provides substantial absorption data, but it often does not accurately predict drug absorption in vivo. In the Caco-2 system, the compound is typically added in a dissolved state at concentrations much lower than the actual concentrations present in the gastrointestinal tract, and the actual absorption can be misjudged when the relationship between solubility and dose is nonlinear. Moreover, the Caco-2 system may underestimate the 
FIG. 2.
Relationship between the percentage of oral dose absorption and permeability across Caco-2 monolayers (left) and rat jejunum using the Ussing chamber (right) with reference drugs for P-gp. Caco-2 data were quoted from Adachi et al. 6 Briefly, the concentrations of compounds were as follows: cimetidine (64.5 nM), digoxin (52.6 nM), quinidine (50 nM), and verapamil (11.8 nM). Transcellular transport experiments were carried out in Hank's balanced salt solution. The transported amount was determined at 1 and 2 h. Each point represents the mean of 2 to 3 experiments. absorption of compounds with an affinity for P-gp, which is expressed both in the gastrointestinal tract and in Caco-2 cells. Consequently, it has not been possible to accurately predict absorption percentage for all compounds. [2] [3] [4] [5] [6] Thus, there has not been a universal method that can be used to accurately predict the absorption percentage during the early stages of drug discovery. Rats received an intravenous dose of fexofenadine (1 mg/kg) and ketoconazole (1 mg/kg) and an oral dose of fexofenadine (3 mg/kg) and ketoconazole (3 mg/kg). The plasma and urine concentrations were determined using liquid chromatography-tandem mass spectrometry. F = bioavailability; F h = hepatic bioavailability; F a = absorption rate; F g = bioavailability in the small intestine; CL tot = total clearance; CL r = renal clearance; CL h = hepatic clearance. Each value represents the mean of 3 experiments. Here, we propose a relatively simple in vitro method for estimating the absorption percentage. An Ussing chamber with a pH 6.0 buffer is used in this technique, the concentration of the added compound is around 1 mM (solubilization is not required), and the system is monitored for 2 h. This method has several advantages: a very good correlation between the membrane permeability and the absorption percentage even for compounds that have an affinity for P-gp; a more gradual slope for the absorption percentage versus in vitro rat jejunum permeability plot than in studies using Caco-2, allowing a more accurate prediction of the absorption percentage; and, in contrast to the Caco-2 assay, the ability to measure absorption of compounds that are incompletely dissolved.
Improvement of Absorption Screening
The suitability of the concentration of the added compound in this technique corresponds to the state (maximum concentration) of the drug in the gastrointestinal tract after oral administration in rats (3 mg per 5 mL/kg for a compound having a molecular weight of 500). Provided that the compound is absorbed by simple diffusion and that a linear relationship between the concentration and the membrane permeability rate can be shown, the membrane permeability coefficient can be easily estimated. On the other hand, the Km value for the gastrointestinal transporter will be in the range of several µM if the affinity for the transporter(s) is high. For concentrations at which the Km value is exceeded (mM), it is believed that active transport will reach the point of saturation, and the contribution of passive transport will rise as the concentration is increased. When we evaluated the relationship between membrane permeability and added compound concentration, a good relationship was observed using compounds which are absorbed by passive diffusion, but some compounds exhibited a saturation curve (data not shown). In addition, Chiou et al 2 described the dominantly passive diffusion process in the case of P-gp saturation in the intestine as oral dose increases.
The solubility of the drug is an important factor in the analysis of its permeability and is therefore an important factor in its absorption. Although higher solubility is better for the membrane permeability, we believe that solubility is not a major influence on the permeability because the solubility is the maximum soluble concentration, not the rate of the dissolution. When the added concentration of the drug in the Ussing chamber cell corresponded to the saturation of P-gp transport, some drugs exhibited precipitation in the buffer, indicating that the actual dissolved concentration became lower than the added concentration. This technique may thus allow evaluation of not only the contribution of P-gp, but also the solubility and membrane permeability under the notion that only the dissolved drug is absorbed. Accordingly, regardless of the physicochemical properties or the affinity for the intestinal transporter(s), this technique can predict the absorption percentage in the linear dose-dependent state. Furthermore, the solubility did not affect prediction of the absorption percentage in this system, but it might be useful to compare the absorption between suspension and solutions generated by the addition of a solubilizing reagent.
Consequently, if in vitro rat jejunum permeability can be accurately calculated using this technique, it also becomes possible to estimate the absorption percentage in rats. Because it is known that absorption percentage in rats and humans is virtually the same, 7 the accurate calculation of absorption percentage in rats is considered to be extremely useful. [8] [9] [10] Clinical interactions are a concern for compounds that have an affinity for P-gp and other transporters such as the multidrug resistance-associated protein. Although P-gp is expressed in many tissues, including the brain, small intestine, and liver, the contribution of this transporter in the small intestine and liver (which play a major role in pharmacokinetics) has yet to be established. Therefore, even when drug-drug interactions are observed between such compounds, it is difficult to determine or even estimate whether the interaction is occurring in absorption, uptake, and/or excretion. The guiding hypothesis is that drugs with an affinity for P-gp have intrinsically good absorption properties 11, 12 and that even if intestinal P-gp is inhibited, any change in this contribution would not be significant. However, no theories have accurately described the contribution of P-gp in the small intestine.
We investigated the membrane permeability using drugs with an affinity for P-gp and observed the same in vitro rat jejunum permeability, regardless of whether the drug was added alone or concomitantly with another drug to the same cell of the Ussing chamber. If the same examination was performed using Caco-2, we would only observe an inhibition effect, resulting in changes in the membrane permeability rates in both the direction of absorption and efflux. However, the Caco-2 system does not allow evaluation of the contribution of the P-gp. In our Ussing chamber system, we were able to show that drugs with an affinity for P-gp have the same membrane permeability regardless of whether they were added alone or in combination with other drugs, suggesting that the P-gp has a minimal contribution to intestinal absorption. Various transporters have been evaluated in previous in vitro studies, but there is no method that evaluates the final clinical effects of absorption percentage and drug interactions. The present technique is believed to obtain useful information regarding the contribution of intestinal transporter(s).
The absorption percentage predicted by this method was almost the same, even when multiple types of compound were simultaneously added to the same well in the Ussing chamber or when a compound was added alone. This suggests that simultaneous evaluation using cassette dosing is possible with this method during the initial screening stages of drug development.
Lastly, we investigated the contribution of the intestinal P-gp in vivo. We found that the inhibition of P-gp (which functions as an efflux transporter in the small intestine) with ketoconazole had no effect on the F a F g of fexofenadine. This agreed with the finding that the absorption percentage for fexofenadine was unaffected by the addition of ketoconazole in the Ussing chamber. Similarly, it is reported that ketoconazole had no effect on the absorption of fexofenadine in clinical trials, 13 thus suggesting that the contribution of intestinal P-gp is minimal. Thus, both clinical and in vivo findings indicate that our Ussing chamber technique can accurately predict drug-drug interactions.
In summary, this method allows the in vitro estimation of the absolute absorption percentage of compounds, which includes active transport associated with absorption and excretion via transporters expressed in the small intestine, and passive diffusion including transport through intercellular spaces and paracellular transport, regardless of whether the tested compounds are in solution or suspension. This method is also believed to be very useful as a means for considering the effects of various drug-drug interactions on absorption.
